Cellular and Molecular Life Sciences

, Volume 64, Issue 18, pp 2334–2350

RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases

Authors

  • M. Baud’huin
    • Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, EA3822Université de Nantes, Nantes Atlantique Universités
    • INSERM, ERI 7
  • F. Lamoureux
    • Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, EA3822Université de Nantes, Nantes Atlantique Universités
    • INSERM, ERI 7
  • L. Duplomb
    • Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, EA3822Université de Nantes, Nantes Atlantique Universités
    • INSERM, ERI 7
  • F. Rédini
    • Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, EA3822Université de Nantes, Nantes Atlantique Universités
    • INSERM, ERI 7
    • Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, EA3822Université de Nantes, Nantes Atlantique Universités
    • INSERM, ERI 7
    • CHU de Nantes
Review

DOI: 10.1007/s00018-007-7104-0

Cite this article as:
Baud’huin, M., Lamoureux, F., Duplomb, L. et al. Cell. Mol. Life Sci. (2007) 64: 2334. doi:10.1007/s00018-007-7104-0

Abstract.

1997 saw the identification of a novel set of proteins within the tumor necrosis factor (TNF)/TNF receptor families that are required for the control of bone remodeling. Therefore, these receptors, receptor activator of nuclear factor kappa B (RANK), osteoprotegerin (OPG) and their ligand RANK ligand (RANKL) became the critical molecular triad controlling osteoclastogenesis and pathophysiologic bone remodeling. However, the establishment of the corresponding knock-out and transgenic mice revealed unexpected results, most particularly, the involvement of these factors in the vascular system and immunity. Thus, the OPG/RANK/RANKL molecular triad appears to be associated with vascular calcifications and plays a pivotal function in the development of the immune system through dendritic cells. OPG/RANK/RANKL thus constitute a molecular bridge spanning bone metabolism, vascular biology and immunity. This review summarizes recent knowledge of OPG/RANK/RANKL interactions and activities as well as the current evidence for their participation in osteoimmunology and vascular diseases. In fine, the targeting of the OPG/RANK/RANKL axis as novel therapeutic approaches will be discussed.

Keywords.

RANKLosteoprotegerinbone remodelingosteoclastosteolysisosteoimmunologycardiovascular disease

Copyright information

© Birkhäuser Verlag, Basel 2007